

May 19, 2022

DCS-CRD BSE Limited First Floor, New Trade Wing Rotunda Building, Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400 023 Fax No.2272 3121/2037/2039	Listing Compliance National Stock Exchange of India Ltd. Exchange Plaza, 5 <sup>th</sup> Floor Plot No.C/1, 'G'Block, Bandra- Kurla Complex Bandra East Mumbai 400 051 Fax No.2659 8237/8238
Stock Code: 543213	Stock Code: ROSSARI

Dear Sir/Madam,

**Sub: Outcome of Board Meeting held on Thursday, May 19, 2022**

**Ref.: Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015**

With regards to the captioned matter and in compliance with the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulation, 2015 ("Listing Regulations"), we wish to inform you that at the meeting of the Board of Directors of the Company, which commenced at 04:00 P.M. and concluded at 10:30 P.M. today i.e. Thursday, May 19, 2022, the Board of Directors have inter alia approved the following:

1. Audited Financial Results (Standalone and Consolidated) for the Financial Year ended March 31, 2022, Audited Annual Financial Statements (Standalone and Consolidated) for the Financial Year ended March 31, 2022 together with Auditor's Report with unmodified opinion thereon. The Audited Financial Results approved by the Board of Directors together with Statutory Auditor's Report thereon and a Declaration pursuant to Regulation 33(d) of Listing Regulation as amended is enclosed herewith.
2. Final Dividend of 25% (i.e. Re. 0.50 /- per share) on Equity Shares of the Face Value of Rs. 2/- each for the Financial Year ended March 31, 2022, subject to approval of the Shareholders at the forthcoming Annual General Meeting ("AGM") of the Company. Information regarding Book closure and record date for payment of Final dividend will be intimated separately.
3. Amendment in the Object Clause of the Company and adoption of new clause III(B) [Matters which are necessary for furtherance of the Objects specified in clause III (A)] of the Memorandum of Association ("MOA") of the Company, subject to approval of the shareholders at the forthcoming AGM and such other approvals as may be necessary.
4. Convening the 13<sup>th</sup> Annual General Meeting of the Members of the Company on Friday, July 15, 2022 through Other Audio Visual Means (OAVM) as permitted under the Ministry of Corporate Affairs Circular dated May 05, 2022 and read with the SEBI Circular No. SEBI/HO/CFD/CMD2/CIR/P/2022/62 dated May 13, 2022 allowing the Companies to convene General Meetings electronically.



## ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company), CIN: L24100MH2009PLC194818

Regd. Office : 201 A - B, 2<sup>nd</sup> Floor, Akruiti Corporate Park, L.B.S Marg, Next to GE Gardens, Kanjurmarg (W) Mumbai - 400078, India. T : +91-22-6123 3800 F : +91-22-2579 6982

Factory : Plot No. 10 & 11, Survey No. 90/1/10/ & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. T : 0260-669 3000

: Plot No. D3/24/3, Opposite ATC Tyre Phase III, G.I.D.C Dahej, Village Galanda, Taluka Vagra, Bharuch-Gujarat - 392130, India. T : +91 2641-3505 03

info@rossari.com

www.rossari.com

The aforesaid Audited Financial Results were reviewed by the Audit Committee and subsequently approved and taken on record by the Board of Directors of the Company at their respective meetings held today i.e. May 19, 2022.

The aforesaid information will also be available on Company's website at [www.rossari.com](http://www.rossari.com).

The same may please be taken on record and suitably disseminated to all concerned.

Thanking you,  
Yours Sincerely,  
**For Rossari Biotech Limited**



Parul Gupta  
**Company Secretary & Compliance Officer**  
Membership No.: A38895

Encl.: as above

## **ROSSARI BIOTECH LIMITED**

(An ISO 9001:2015 & 14001:2015 Certified Company), CIN: L24100MH2009PLC194818

**Regd. Office** : 201 A - B, 2<sup>nd</sup> Floor, Akruti Corporate Park, L.B.S Marg, Next to GE Gardens, Kanjurmarg (W) Mumbai - 400078, India. T : +91-22-6123 3800 F : +91-22-2579 6982

**Factory** : Plot No. 10 & 11, Survey No. 90/1/10/ & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. T : 0260-669 3000

: Plot No. D3/24/3, Opposite ATC Tyre Phase III, G.I.D.C Dahej, Village Galanda, Taluka Vagra, Bharuch-Gujarat - 392130, India. T : +91 2641-3505 03

[info@rossari.com](mailto:info@rossari.com)

[www.rossari.com](http://www.rossari.com)

**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE  
FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF  
ROSSARI BIOTECH LIMITED**

**Opinion and Conclusion**

We have (a) audited the Standalone Financial Results for the year ended March 31, 2022 and (b) reviewed the Standalone Financial Results for the quarter ended March 31, 2022 (refer 'Other Matter' section below), which were subject to limited review by us, both included in the accompanying "Statement of Standalone Financial Results for the Quarter and Year Ended March 31, 2022" of Rossari Biotech Limited ("the Company"), ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

**(a) Opinion on Annual Standalone Financial Results**

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended March 31, 2022:

- i. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the year then ended.

**(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended  
March 31, 2022**

With respect to the Standalone Financial Results for the quarter ended March 31, 2022, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2022, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

*ML*  
*pd*

# **Deloitte Haskins & Sells LLP**

## **Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2022**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2022 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

### **Management's Responsibilities for the Statement**

This Statement which includes the Standalone Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended March 31, 2022 has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2022 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

### **Auditor's Responsibilities**

#### **(a) Audit of the Standalone Financial Results for the year ended March 31, 2022**

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2022 as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists.

*ml*  
*pd*

## **Deloitte Haskins & Sells LLP**

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors (i) in planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.



## **Deloitte Haskins & Sells LLP**

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

### **(b) Review of the Standalone Financial Results for the quarter ended March 31, 2022**

We conducted our review of the Standalone Financial Results for the quarter ended March 31, 2022 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### **Other Matter**

- The Statement includes the results for the Quarter ended March 31, 2022 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report on the Statement is not modified in respect of this matter.

For Deloitte Haskins & Sells LLP  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



Manoj H. Dama  
(Partner)  
(Membership No. 107723)  
(UDIN: 22107723AJGLIW7962)

Place: Mumbai  
Date: May 19, 2022



# ROSSARI BIOTECH LIMITED

(AN ISO9001:2005 & 14001:2015 Certified Company)

Regd. Office : 201 A & B, 2<sup>nd</sup> Floor, Akruti Corporate Park, L.B.S. Marg, Next to GE Gardens, Kanjurmarg (W) Mumbai – 400078  
T +91-22-6123 3800 F +91-22- 25796982 E info@rossari.com W www.rossari.com CIN: L24100MH2009PLC194818



## STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2022

Rs. In million

Particulars	Quarter ended			Year Ended	
	31st March, 2022	31st December, 2021	31st March, 2021	31st March, 2022	31st March, 2021
	Unaudited	Unaudited	Unaudited	Audited	Audited
	Refer note 4		Refer note 4		
<b>I INCOME</b>					
Revenue from operations	2,616.41	2,686.44	2,014.82	10,728.44	6,904.14
Other Income	19.35	57.10	16.97	127.00	97.23
<b>Total Income</b>	<b>2,635.76</b>	<b>2,743.54</b>	<b>2,031.79</b>	<b>10,855.44</b>	<b>7,001.37</b>
<b>II EXPENSES</b>					
Cost of materials consumed	1,782.96	1,830.96	1,320.27	7,079.83	4,338.78
Purchase of stock-in-trade	147.72	312.59	67.38	1,222.89	249.86
Changes in inventories of finished goods and work-in-progress	67.25	(55.02)	(8.94)	(103.38)	(72.21)
Employee benefits expense	127.74	110.12	94.56	435.27	366.60
Finance costs	6.05	4.37	8.04	25.45	29.92
Depreciation and amortization expenses	70.80	67.64	69.36	262.68	220.74
Other expenses	216.08	227.93	188.94	865.90	807.70
<b>Total Expenses</b>	<b>2,418.60</b>	<b>2,498.59</b>	<b>1,739.61</b>	<b>9,788.64</b>	<b>5,941.39</b>
<b>III Profit before exceptional items and tax [I-II]</b>	<b>217.16</b>	<b>244.95</b>	<b>292.18</b>	<b>1,066.80</b>	<b>1,059.98</b>
<b>IV Exceptional items</b>	-	-	-	-	-
<b>V Profit before tax [III-IV]</b>	<b>217.16</b>	<b>244.95</b>	<b>292.18</b>	<b>1,066.80</b>	<b>1,059.98</b>
<b>VI Tax Expense</b>					
Current tax charge	59.48	64.08	81.83	287.15	275.30
Deferred tax charge/(credit)	(11.06)	(1.81)	(3.64)	(15.09)	(6.34)
<b>Total Tax Expense</b>	<b>48.42</b>	<b>62.27</b>	<b>78.19</b>	<b>272.06</b>	<b>268.96</b>
<b>VII Profit after tax [V-VI]</b>	<b>168.74</b>	<b>182.68</b>	<b>213.99</b>	<b>794.74</b>	<b>791.02</b>
<b>VIII Other comprehensive income / (loss)</b>					
<b>A Items that will not be reclassified to profit or loss</b>					
i Remeasurements of the defined benefit plans	(1.08)	0.42	3.78	0.18	1.67
ii Income tax relating to items that will not be reclassified to profit or loss	0.28	(0.11)	(0.94)	(0.04)	(0.42)
<b>B Items that will be reclassified subsequently to profit or loss</b>	-	-	-	-	-
<b>Total other comprehensive income/(loss)</b>	<b>(0.80)</b>	<b>0.31</b>	<b>2.84</b>	<b>0.14</b>	<b>1.25</b>
<b>IX Total comprehensive income (VII + VIII)</b>	<b>167.94</b>	<b>182.99</b>	<b>216.83</b>	<b>794.88</b>	<b>792.27</b>
Paid up equity share capital (Face value of Rs 2 per share)	110.11	110.11	103.86	110.11	103.86
Other equity				7,735.13	3,940.58
<b>X Earnings per equity share (in Rs.)</b>					
Basic	3.06*	3.32*	4.12*	14.49	15.34
Diluted	3.05*	3.30*	4.10*	14.40	15.25

\*Not annualized



## ROSSARI BIOTECH LIMITED

Standalone Balance Sheet as at 31st March, 2022

Rs. In million

Particulars	As at	As at
	31st March, 2022	31st March, 2021
	Audited	Audited
<b>ASSETS</b>		
<b>NON-CURRENT ASSETS</b>		
(a) Property, Plant and Equipment	1,650.98	1,600.88
(b) Right of Use - Assets	68.61	69.38
(c) Capital Work-in-Progress	8.42	3.19
(d) Goodwill	10.60	-
(e) Other Intangible Assets	43.56	37.27
(f) Financial Assets		
(i) Investments	3,718.50	92.53
(ii) Other Financial Assets	16.14	205.48
(g) Income Tax Assets (Net)	21.44	21.19
(h) Deferred Tax Assets (Net)	10.27	0.52
(i) Other Non-current Assets	30.12	18.01
<b>TOTAL NON-CURRENT ASSETS</b>	<b>5,578.64</b>	<b>2,048.45</b>
<b>CURRENT ASSETS</b>		
(a) Inventories	1,074.41	885.21
(b) Financial Assets		
(i) Investments	90.07	-
(ii) Trade Receivables	1,809.58	1,373.22
(iii) Cash and Cash Equivalents	267.42	148.31
(iv) Bank Balances other than (iii) above	80.68	711.51
(v) Loans	26.99	24.44
(vi) Other Financial Assets	8.51	31.84
(c) Other Current Assets	323.02	220.61
<b>TOTAL CURRENT ASSETS</b>	<b>3,680.68</b>	<b>3,395.14</b>
<b>TOTAL ASSETS</b>	<b>9,259.32</b>	<b>5,443.59</b>
<b>EQUITY AND LIABILITIES</b>		
<b>EQUITY</b>		
(a) Equity Share Capital	110.11	103.86
(b) Other Equity	7,735.13	3,940.58
<b>TOTAL EQUITY</b>	<b>7,845.24</b>	<b>4,044.44</b>
<b>LIABILITIES</b>		
<b>NON-CURRENT LIABILITIES</b>		
(a) Provisions	12.28	9.87
<b>TOTAL NON-CURRENT LIABILITIES</b>	<b>12.28</b>	<b>9.87</b>
<b>CURRENT LIABILITIES</b>		
(a) Financial Liabilities		
(i) Trade Payables		
a) total outstanding dues of Micro Enterprises and Small Enterprises	144.21	150.54
b) total outstanding dues of Creditors other than Micro Enterprises and Small Enterprises	1,013.89	1,085.88
(ii) Other Financial Liabilities	112.62	104.96
(b) Other Current Liabilities	68.45	32.61
(c) Provisions	9.14	6.95
(d) Current Tax Liabilities (Net)	53.49	8.34
<b>TOTAL CURRENT LIABILITIES</b>	<b>1,401.80</b>	<b>1,389.28</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>9,259.32</b>	<b>5,443.59</b>





## ROSSARI BIOTECH LIMITED

## Standalone Statement of Cash Flow for the year ended 31st March, 2022

Particulars	Rs. In million	
	For the year ended	For the year ended
	31st March, 2022	31st March, 2021
	Audited	Audited
<b>A Cash flows from operating activities</b>		
Profit before tax	1,066.80	1,059.98
<b>Adjustments for:</b>		
Depreciation and amortisation expenses	262.68	220.74
Gain on disposal of property, plant and equipment	(6.87)	(4.32)
Provision for expected credit loss	1.05	0.15
Share-based payments expenses	15.50	15.30
Write down of value of Inventory to net realisable value	4.46	4.71
Finance Cost	25.45	29.92
Dividend Income	-	(32.71)
Interest Income	(49.77)	(49.59)
Net (gain) on sale/fair value of investments	(12.52)	0.01
Net (gain)/loss arising on derivative instruments measured at fair value through profit or loss	(4.36)	-
Deemed income on investment	-	(0.12)
Net foreign exchange gain	-	(0.01)
<b>Operating profit before working capital changes</b>	<b>1,302.42</b>	<b>1,244.06</b>
<b>Changes in :</b>		
Trade Receivables and other assets	(481.04)	(361.41)
Inventories	(182.89)	(308.21)
Trade Payables and other liabilities	(65.08)	255.77
<b>Cash generated from Operations</b>	<b>573.41</b>	<b>830.21</b>
Income taxes paid (net of refunds)	(242.25)	(309.28)
<b>Net cash flows generated from operating activities</b>	<b>331.16</b>	<b>520.93</b>
<b>B Cash flows from investing activities</b>		
Net (Investment) / redemption of Mutual Funds	(77.55)	105.60
Payments to acquire subsidiaries	(3,530.87)	(45.91)
Payment to acquire balance stake in subsidiary	(20.00)	-
Payments to acquire associate	(75.10)	-
Loans given to subsidiary companies	(206.30)	(32.50)
Loans repaid by subsidiary companies	204.30	8.80
Dividend Received	-	32.71
Interest Received	56.43	42.34
Payments to acquire property, plant and equipment (including Capital work in progress) and intangible assets	(324.58)	(579.88)
Proceeds from sale of property, plant and equipment	19.11	21.86
Payment for transfer of assets under Business combination	(52.50)	-
Decrease in bank balances not considered as cash and cash equivalents (net)	825.90	76.99
<b>Net cash flows used in investing activities</b>	<b>(3,181.16)</b>	<b>(369.99)</b>
<b>C Cash flows from financing activities</b>		
Repayment of short term borrowing (net)	-	(270.52)
Repayment of long-term borrowings	-	(398.77)
Interest paid	(18.41)	(26.40)
Proceeds from Issue of equity shares (net of share issue expenses)	3,015.05	426.53
Dividend paid on equity shares	(27.53)	(25.38)
<b>Net cash flow generated from / (used in ) financing activities</b>	<b>2,969.11</b>	<b>(294.54)</b>
<b>Net increase / (decrease) in cash and cash equivalents (A+B+C)</b>	<b>119.11</b>	<b>(143.60)</b>
<b>Opening Cash and cash equivalents</b>	<b>148.31</b>	<b>291.90</b>
Effects of exchange rate changes on the balance of cash and cash equivalents held in foreign currencies	-	0.01
<b>Closing Cash and cash equivalents</b>	<b>267.42</b>	<b>148.31</b>

hd ml



**Notes:**

- 1 The financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 19th May, 2022.
- 2 The standalone financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standard (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- 3 The Company is mainly engaged in the business of manufacturing of Specialty Chemicals for Textile, Home and Personal Care, and Performance Chemicals industries. There are no reportable segments in accordance with IND AS 108 – Operating Segments.
- 4 The Statement includes figures for the quarter ended 31st March, 2022 being the balancing figure of the audited figures for the year ended 31st March, 2022 and figures for the nine months ended 31st December, 2021 subjected to limited review. There are no material adjustments made in the results of the quarter ended 31st March, 2022 which pertains to the earlier periods.

The Statement includes the results for the quarter ended 31st March, 2021 being the balancing figure of audited figures in respect of full financial year and the published year to date figures upto the third quarter of the financial year ended 31st March, 2021.

- 5 The Board of Directors have recommended final dividend of Re. 0.50 per share (25 percent of the face value of the equity share of face value of Rs. 2 each) for the financial year ended 31st March, 2022.
- 6 The Company has considered the external and internal information for assessing possible impact of COVID-19 on various elements of its financial results, including the recoverability of its assets. The Company will continue to monitor any material changes to future economic conditions and consequential impact on its financial results.



**For ROSSARI BIOTECH LIMITED**

A handwritten signature in blue ink, appearing to read "Edward Menezes".

**EDWARD MENEZES**  
**Executive Chairman**  
DIN:00149205

Place : Mumbai  
Date :19th May, 2022

Handwritten initials in blue ink, "ml" and "ps".



A handwritten letter "M" in blue ink.

**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED  
FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF  
ROSSARI BIOTECH LIMITED**

**Opinion and Conclusion**

We have (a) audited the Consolidated Financial Results for the year ended March 31, 2022 and (b) reviewed the Consolidated Financial Results for the quarter ended March 31, 2022 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Consolidated Financial Results for the Quarter and Year Ended March 31, 2022" of Rossari Biotech Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income of its joint venture and associate for the quarter and year ended March 31, 2022, ("the Statement") being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

**(a) Opinion on Annual Consolidated Financial Results**

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit reports of other auditors on separate financial statements / financial information of subsidiaries, associate and joint venture referred to in Other Matters section below, the Consolidated Financial Results for the year ended March 31, 2022:

i. includes the results of the following entities:

**Parent:**

Rossari Biotech Limited

**List of Subsidiaries:**

Unitop Chemical Private Limited (with effect from August 26, 2021)

Tristar Intermediates Private Limited (with effect from August 31, 2021)

Rossari Personal Care Products Private Limited

Buzil Rossari Private Limited (Joint Venture up to August 31, 2020; Subsidiary with effect from September 1, 2020)

**Joint Venture:**

Hextar Unitop Sendirian Berhad - a joint venture of Unitop Chemicals Private Limited (with effect from August 26, 2021)

*Handwritten signature*

# **Deloitte Haskins & Sells LLP**

## **Associate:**

Romakk Chemicals Private Limited - (with effect from November 25, 2021)

- ii. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- iii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and consolidated total comprehensive income and other financial information of the Group for the year ended March 31, 2022.

## **(b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2022**

With respect to the Consolidated Financial Results for the quarter ended March 31, 2022, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor's Responsibilities section below and based on the consideration of the review reports of the other auditors referred to in Other Matters section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for the quarter ended March 31, 2022, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

## **Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2022**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Group, its associate and joint venture in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended March 31, 2022 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in Other Matters section below, is sufficient and appropriate to provide a basis for our audit opinion.

## **Management's Responsibilities for the Statement**

This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2022, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2022 that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group including its associate and joint venture in accordance with the recognition and measurement principles laid down

ms  
pd

## **Deloitte Haskins & Sells LLP**

in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group and of its associate and joint venture are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and its associate and joint venture and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Parent, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group and of its associate and joint venture are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associate and jointly controlled entities are responsible for overseeing the financial reporting process of the Group and of its associate and joint venture.

### **Auditor's Responsibilities**

#### **(a) Audit of the Consolidated Financial Results for the year ended March 31, 2022**

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended March 31, 2022 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.

ml  
pd

## **Deloitte Haskins & Sells LLP**

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associate and joint venture to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associate and joint venture to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results/ Financial Information of the entities within the Group and its associate and its joint venture to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Annual Consolidated Financial Results of which we are the independent auditors. For the other entities included in the Annual Consolidated Financial Results, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors (i) in planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.

We communicate with those charged with governance of the Parent and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

ML  
18

## **Deloitte Haskins & Sells LLP**

### **(b) Review of the Consolidated Financial Results for the quarter ended March 31, 2022**

We conducted our review of the Consolidated Financial Results for the quarter ended March 31, 2022 in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Statement includes the results of the entities as listed under paragraph (a)(i) of Opinion and Conclusion section above.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

#### **Other Matters**

- The Statement includes the results for the Quarter ended March 31, 2022 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report is not modified in respect of this matter.
- We did not audit the financial statements/financial information of 4 subsidiaries included in the consolidated financial results, whose financial statements/financial information reflect total assets of Rs. 3,956.51 million as at March 31, 2022 and total revenues of Rs. 1,947.44 million and Rs. 4,650.03 million for the quarter and year ended March 31, 2022 respectively, total net profit after tax of Rs. 116.27 million and Rs. 342.88 million for the quarter and year ended March 31, 2022 respectively and total comprehensive income of Rs. 119.26 million and Rs. 344.15 million for the quarter and year ended March 31, 2022 respectively and net cash inflows of Rs. 887.63 million for the year ended March 31, 2022, as considered in the Statement. The consolidated financial results also includes the Group's share of profit after tax of Rs 8.96 million and Rs. 9.44 million for the quarter and year ended March 31, 2022 respectively and Total comprehensive income of Rs. 8.96 million and Rs. 9.44 million for the quarter and year ended March 31, 2022 respectively, as considered in the Statement, in respect of an associate, whose financial statements/financial information have not been audited by us. These financial statements/ financial information have been audited/ reviewed, by other auditors whose reports have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and associate, is based solely on the reports of the other auditors and the procedures performed by us as stated under Auditor's Responsibilities section above.

Our report on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of other auditors.

*ml*  
*ps*

## **Deloitte Haskins & Sells LLP**

- The consolidated financial results also includes the Group's share of profit after tax of Rs 4.31 million and Rs. 6.03 million for the quarter and year ended March 31, 2021 respectively and total comprehensive income of Rs 4.31 million and Rs. 6.03 million for the quarter and year ended March 31, 2021 respectively, as considered in the Statement, in respect of a joint venture, whose financial statements/financial information have not been audited by us. These financial statements/financial information are unaudited and have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this joint venture, is based solely on such unaudited financial statements/financial information. In our opinion and according to the information and explanations given to us by the Board of Directors, these financial statements / financial information are not material to the Group.

Our report on the Statement is not modified in respect of the above matter with respect to our reliance on the financial statements/ financial information certified by the Board of the Directors.

For Deloitte Haskins & Sells LLP  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



Manoj H. Dama  
(Partner)  
(Membership No. 107723)  
(UDIN: 22107723AJGLTK1910)

Place: Mumbai  
Date: May 19, 2022





**ROSSARI BIOTECH LIMITED**  
(AN ISO9001:2005 & 14001:2015 Certified Company)



Regd. Office : 201 A & B, 2<sup>nd</sup> Floor, Akruvi Corporate Park, L.B.S. Marg, Next to GE Gardens, Kanjurmarg (W) Mumbai – 400078  
T +91-22-6123 3800 F +91-22- 25796982 E info@rossari.com W www.rossari.com CIN: L24100MH2009PLC194818

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2022

Rs. in Million

Particulars	Quarter ended			Year Ended	
	31st March, 2022	31st December, 2021	31st March, 2021	31st March, 2022	31st March, 2021
	Unaudited Refer note 4	Unaudited	Unaudited Refer note 4	Audited	Audited
<b>I INCOME</b>					
Revenue from operations	4,389.32	4,284.16	2,182.22	14,829.74	7,093.45
Other Income	19.72	53.55	20.40	119.96	87.04
<b>Total Income</b>	<b>4,409.04</b>	<b>4,337.71</b>	<b>2,202.62</b>	<b>14,949.70</b>	<b>7,180.49</b>
<b>II EXPENSES</b>					
Cost of materials consumed	2,980.04	2,963.20	1,326.10	9,701.17	4,348.06
Purchase of stock-in-trade	224.19	312.59	175.62	1,552.14	358.11
Changes in inventories of finished goods, work-in-progress and stock-in-trade	39.82	(60.10)	4.37	(202.88)	(84.24)
Employee benefits expense	222.07	201.80	115.93	679.29	419.75
Finance costs	48.02	48.42	8.04	126.56	29.92
Depreciation and amortization expenses	165.39	156.70	73.86	480.55	228.29
Other expenses	400.09	389.23	199.63	1,265.59	816.33
<b>Total Expenses</b>	<b>4,079.62</b>	<b>4,011.84</b>	<b>1,903.55</b>	<b>13,602.42</b>	<b>6,116.22</b>
<b>III Profit before Share of profit of joint venture, associate, exceptional items and tax [I-II]</b>	<b>329.42</b>	<b>325.87</b>	<b>299.07</b>	<b>1,347.28</b>	<b>1,064.27</b>
IV Share of profit of joint venture/associate	13.27	1.57	-	15.47	4.11
<b>V Profit before exceptional items and tax [III+IV]</b>	<b>342.69</b>	<b>327.44</b>	<b>299.07</b>	<b>1,362.75</b>	<b>1,068.38</b>
VI Exceptional items	-	-	-	-	-
<b>VII Profit before tax [V-VI]</b>	<b>342.69</b>	<b>327.44</b>	<b>299.07</b>	<b>1,362.75</b>	<b>1,068.38</b>
<b>VIII Tax Expense</b>					
Current tax charge	123.70	151.54	83.51	470.14	276.98
Deferred tax charge/(credit)	(21.82)	(52.05)	(6.49)	(84.34)	(9.06)
<b>Total Tax Expense</b>	<b>101.88</b>	<b>99.49</b>	<b>77.02</b>	<b>385.80</b>	<b>267.92</b>
<b>IX Profit after tax [VII-VIII]</b>	<b>240.81</b>	<b>227.95</b>	<b>222.05</b>	<b>976.95</b>	<b>800.46</b>
<b>X Other comprehensive income / (loss)</b>					
A Items that will not be reclassified to profit or loss					
i Remeasurements of the defined benefit plans	2.61	(1.62)	3.63	1.31	1.52
ii Income tax relating to items that will not be reclassified to profit or loss	(1.06)	0.68	(0.98)	(0.46)	(0.46)
B Items that will be reclassified subsequently to profit or loss	-	-	-	-	-
<b>Total other comprehensive income/(Loss)</b>	<b>1.55</b>	<b>(0.94)</b>	<b>2.65</b>	<b>0.85</b>	<b>1.06</b>
<b>XI Total comprehensive income (IX + X)</b>	<b>242.36</b>	<b>227.01</b>	<b>224.70</b>	<b>977.80</b>	<b>801.52</b>
<b>Profit / Loss for the year attributable to</b>					
Owners of the Company	240.81	227.95	224.27	976.74	802.20
Non Controlling Interest	-	-	(2.22)	0.21	(1.74)
	<b>240.81</b>	<b>227.95</b>	<b>222.05</b>	<b>976.95</b>	<b>800.46</b>
<b>Other Comprehensive Income/(Loss) attributable to</b>					
Owners of the Company	1.55	(0.94)	2.65	0.85	1.06
Non Controlling Interest	-	-	-	-	-
	<b>1.55</b>	<b>(0.94)</b>	<b>2.65</b>	<b>0.85</b>	<b>1.06</b>
<b>Total Comprehensive Income / (loss) attributable to</b>					
Owners of the Company	242.36	227.01	226.92	977.58	803.26
Non Controlling Interest	-	-	(2.22)	0.21	(1.74)
	<b>242.36</b>	<b>227.01</b>	<b>224.70</b>	<b>977.80</b>	<b>801.52</b>
Paid up equity share capital (Face value of Rs 2.00 per share)	110.11	110.11	103.86	110.11	103.86
Other equity	-	-	-	7,941.53	3,983.86
<b>Earnings per equity share (in Rs.)</b>					
Basic	4.37*	4.09*	4.32*	17.81	15.56
Diluted	4.35*	4.07*	4.29*	17.70	15.47

\*Not annualized



**ROSSARI BIOTECH LIMITED**  
**Consolidated Balance sheet as at March 31, 2022**

Particulars	Rs. In million	
	As at March 31, 2022 Audited	As at March 31, 2021 Audited
<b>ASSETS</b>		
<b>NON-CURRENT ASSETS</b>		
(a) Property, Plant and Equipment	3,024.50	1,609.32
(b) Right of Use Assets	441.95	69.38
(c) Capital Work-in-Progress	13.42	3.19
(d) Goodwill	898.58	26.24
(e) Other Intangible Assets	1,706.38	107.60
(f) Investments accounted for using the equity method	241.66	-
(g) Financial Assets		
(i) Investments	2.06	-
(ii) Other Financial Assets	41.01	205.48
(h) Income Tax Assets (Net)	58.17	23.99
(i) Deferred Tax Assets (Net)	13.53	3.07
(j) Other Non-current Assets	33.03	18.01
<b>TOTAL NON- CURRENT ASSETS</b>	<b>6,474.29</b>	<b>2,066.28</b>
<b>CURRENT ASSETS</b>		
(a) Inventories	1,899.32	953.54
(b) Financial Assets		
(i) Investments	115.49	-
(ii) Trade Receivables	3,048.53	1,440.68
(iii) Cash and Cash Equivalents	374.77	152.08
(iv) Bank Balances other than (iii) above	148.75	730.53
(v) Loans	13.91	10.89
(vi) Other Financial Assets	8.83	17.24
(c) Other Current Assets	483.33	242.23
<b>TOTAL CURRENT ASSETS</b>	<b>6,092.93</b>	<b>3,547.19</b>
<b>TOTAL ASSETS</b>	<b>12,567.22</b>	<b>5,613.47</b>
<b>EQUITY AND LIABILITIES</b>		
<b>EQUITY</b>		
(a) Equity Share Capital	110.11	103.86
(b) Other Equity	7,941.53	3,983.86
Equity Attributable to Owners of the Company	<b>8,051.64</b>	<b>4,087.72</b>
Non controlling interests	-	-
<b>TOTAL EQUITY</b>	<b>8,051.64</b>	<b>4,087.72</b>
<b>LIABILITIES</b>		
<b>NON-CURRENT LIABILITIES</b>		
(a) Financial Liabilities		
(i) Other Financial Liabilities	850.27	-
(b) Provisions	29.18	11.01
(c) Deferred Tax Liabilities (Net)	689.49	12.88
<b>TOTAL NON CURRENT LIABILITIES</b>	<b>1,568.94</b>	<b>23.89</b>
<b>CURRENT LIABILITIES</b>		
(a) Financial Liabilities		
(i) Borrowings	84.27	-
(ii) Trade Payables		
a) total outstanding dues of Micro Enterprises and Small Enterprises	211.54	150.54
b) total outstanding dues of Creditors other than Micro Enterprises and Small Enterprises	1,649.97	1,160.59
(iii) Other Financial Liabilities	815.67	105.33
(b) Other Current Liabilities	97.37	68.82
(c) Provisions	15.99	8.24
(d) Current Tax Liabilities (Net)	71.83	8.34
<b>TOTAL CURRENT LIABILITIES</b>	<b>2,946.64</b>	<b>1,501.86</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>12,567.22</b>	<b>5,613.47</b>



Handwritten initials and a signature in blue ink at the bottom left of the page.

## ROSSARI BIOTECH LIMITED

## Consolidated Statement of Cash Flow for the year ended March 31, 2022

Particulars	<i>Rs. In million</i>	
	For the Year ended March 31, 2022	For the Year ended March 31, 2021
	Audited	Audited
<b>A Cash flows from operating activities</b>		
Profit before tax	1,362.75	1,068.38
<b>Adjustments for:</b>		
Depreciation and amortization expenses	480.55	228.29
Gain on disposal of property, plant and equipment (net)	(6.38)	(4.32)
Provision for expected credit loss	8.87	0.71
Share-based payments expenses	18.31	16.27
Write down of value of Inventory to net realisable value	4.46	4.71
Finance Costs	126.56	29.92
Dividend Income	(0.07)	(0.05)
Interest Income	(40.67)	(42.65)
Share of profit in Joint Venture/Associate	(15.47)	(4.11)
Fair value gain on acquisition date from fair value of the Company's previously held equity interest in the acquiree	-	(23.02)
Net (gain) on sale/fair value of investments	(9.82)	0.08
Net (gain)/loss arising on derivative instruments measured at fair value through profit or loss	(4.36)	-
Net foreign exchange gain	-	(0.01)
<b>Operating profit before working capital changes</b>	<b>1,924.73</b>	<b>1,274.20</b>
<b>Changes in:</b>		
Trade Receivables and other assets	(425.28)	(404.50)
Inventories	(481.85)	(320.25)
Trade Payables and other liabilities	(222.78)	241.70
<b>Cash generated from Operations</b>	<b>794.82</b>	<b>791.15</b>
Income taxes paid (net of refunds)	(501.24)	(313.48)
<b>Net cash flows generated from operating activities</b>	<b>293.58</b>	<b>477.67</b>
<b>B Cash flows from investing activities</b>		
Net proceeds from redemption of investments in Mutual Funds	15.54	137.22
Payments to acquire subsidiaries (net of cash acquired)	(3,402.41)	(43.39)
Payments to acquire associate	(75.10)	-
Payments to acquire balance stake in subsidiary	(20.00)	-
Payment for acquisition of assets under Business combination	(52.50)	-
Dividend Received	0.07	0.05
Interest Received	49.62	35.22
Payments to acquire property, plant and equipment (including Capital work in progress) and intangible assets	(382.25)	(580.84)
Proceeds from sale of property, plant and equipment	19.11	21.86
Decrease in bank balances not considered as cash and cash equivalents (net)	859.13	58.09
<b>Net cash flow used in investing activities</b>	<b>(2,988.79)</b>	<b>(371.79)</b>
<b>C Cash flows from financing activities</b>		
Repayment of short term borrowings (net)	(48.12)	(270.52)
Repayment of long-term borrowings	-	(339.60)
Interest paid	(21.50)	(38.95)
Proceeds from Issue of equity shares (net of share issue expenses)	3,015.05	426.53
Dividend paid on equity shares	(27.53)	(25.38)
Issue of Equity shares to minority shareholders	-	2.00
<b>Net cash flow generated from / (used in ) financing activities</b>	<b>2,917.90</b>	<b>(245.92)</b>
<b>Net increase/(decrease) in cash and cash equivalents (A+B+C)</b>	<b>222.69</b>	<b>(140.04)</b>
<b>Opening Cash and cash equivalents</b>	<b>152.08</b>	<b>292.11</b>
Effects of exchange rate changes on the balance of cash and cash equivalents held in foreign currencies	-	0.01
<b>Closing Cash and cash equivalents</b>	<b>374.77</b>	<b>152.08</b>

ml  
kd



**Notes:**

- 1 The financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 19th May, 2022.
- 2 The consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standard (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- 3 The Group is mainly engaged in the business of manufacturing of Specialty Chemicals for Textile, Home and Personal Care, Performance Chemicals and Animal Health and Nutrition industries. There are no reportable segments in accordance with IND AS 108 – Operating Segments.
- 4 The Statement includes figures for the quarter ended 31st March, 2022 being the balancing figure of the audited figures for the year ended 31st March, 2022 and figures for the nine months ended 31st December, 2021 subjected to limited review. There are no material adjustments made in the results of the quarter ended 31st March, 2022 which pertains to the earlier periods (Refer note 5 below).

The Statement includes the results for the quarter ended 31st March, 2021 being the balancing figure of audited figures in respect of full financial year and the published year to date figures upto the third quarter of the financial year ended 31st March, 2021.

- 5 During the quarter ended 30th September, 2021, the Parent has completed the acquisition of 65% equity shares of Unitop Chemicals Private Limited (UCPL) and 76% equity shares of Tristar Intermediates Private Limited (TIPL). The Group had accounted for the aforesaid acquisitions in its books as a business acquisition in terms of Ind AS - 103 - 'Business Combination'. Such Business Combination required that the assets and liabilities to be fair valued in the consolidated financial results at the acquisition date. The acquisition date for the business combination for UCPL was 26th August, 2021 and TIPL was 1st September, 2021 and accordingly it has been accounted on a provisional fair value basis.

During the current quarter, the Parent has finalised the fair valuation of assets and liabilities which had been accounted on a provisional basis in the quarter ended 30th September, 2021. The determination of such fair value has been carried out by the independent agency appointed by the Parent. In accordance with Ind AS 103 - 'Business Combination', the consolidated financial results have been revised for the quarter ended 31st December, 2021. The financial effect of the revision - increase/(decrease) to the figures in the consolidated financial results are given below:

**Consolidated Financial Results:**

Particulars	Quarter ended December 31, 2021
Finance costs	13.52
Depreciation and amortisation expenses	(21.49)
Profit before tax	7.97
Tax Expenses	5.41
Profit after tax	2.56
Total other comprehensive income/(loss)	2.56

Results for the quarter and year ended 31st March, 2022 includes results of UCPL and TIPL from the date of acquisition till 31st March, 2022 and hence the results for current quarter and year ended 31st March, 2022 are not comparable with the previous periods.

- 6 During the previous quarter ended 31st December 2021, the Parent Company has completed the process of the acquisition / subscription of equity shares of 50.10% of the issued and paid -up share capital of Romakk Chemicals Private Limited ("Romakk"), an associate of the Company, at an aggregate consideration of Rs.75.10 million.

As per IND AS 103, allocation of purchase consideration towards the fair value of assets and liabilities and determination of goodwill are, done on a provisional basis, pending the final determination.

- 7 The Board of Directors have recommended final dividend of Re. 0.50 per share (25 percent of the face value of the equity share of face value of Rs. 2 each) for the financial year ended 31st March, 2022.
- 8 The Group has considered the external and internal information for assessing possible impact of COVID-19 on various elements of its financial results, including the recoverability of its assets. The Group will continue to monitor any material changes to future economic conditions and consequential impact on its financial results.

*Handwritten initials: md*



For ROSSARI BIOTECH LIMITED

*Handwritten signature of Edward Menezes*

EDWARD MENEZES  
Executive Chairman  
DIN:00149205